[go: up one dir, main page]

CY1111450T1 - Ενωσεις που αναστελλουν τη φλεγμονη - Google Patents

Ενωσεις που αναστελλουν τη φλεγμονη

Info

Publication number
CY1111450T1
CY1111450T1 CY20111100430T CY111100430T CY1111450T1 CY 1111450 T1 CY1111450 T1 CY 1111450T1 CY 20111100430 T CY20111100430 T CY 20111100430T CY 111100430 T CY111100430 T CY 111100430T CY 1111450 T1 CY1111450 T1 CY 1111450T1
Authority
CY
Cyprus
Prior art keywords
compounds
pro
against inflammation
relates
inflammation
Prior art date
Application number
CY20111100430T
Other languages
English (en)
Inventor
Dr Thomas Luger
Original Assignee
Luger, Thomas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Luger, Thomas filed Critical Luger, Thomas
Publication of CY1111450T1 publication Critical patent/CY1111450T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/85—Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C12N2501/86—Melanocyte-stimulating hormone [MSH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση αφορά τη χρησιμοποίηση μιας ένωσης του τύπου Lys-X, όπου Χ είναι μια υδροξυλομάδα, μια αμινομάδα, μια αλκοξυ-ομάδα, Pro ή Pro-Thr, ή ένα από φαρμακευτικής άποψης συμβατό άλας αυτών, για τη θεραπευτική αγωγή φλεγμονών. Η εφεύρεση αφορά επίσης τη χρησιμοποίηση αMSH για την επαγωγή ανοχής.
CY20111100430T 2001-02-14 2011-05-04 Ενωσεις που αναστελλουν τη φλεγμονη CY1111450T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10106852A DE10106852A1 (de) 2001-02-14 2001-02-14 Entzündungshemmende Verbindungen
EP06024288A EP1749524B1 (de) 2001-02-14 2002-02-08 Entzündungshemmende Verbindungen

Publications (1)

Publication Number Publication Date
CY1111450T1 true CY1111450T1 (el) 2015-08-05

Family

ID=7674019

Family Applications (4)

Application Number Title Priority Date Filing Date
CY20071100596T CY1106563T1 (el) 2001-02-14 2007-05-07 Φλεγμονο-ανασταλτικες ενωσεις
CY20111100430T CY1111450T1 (el) 2001-02-14 2011-05-04 Ενωσεις που αναστελλουν τη φλεγμονη
CY20131100431T CY1114024T1 (el) 2001-02-14 2013-05-30 Ενωσεις που αναστελλουν τη φλεγμονη
CY20131100702T CY1114214T1 (el) 2001-02-14 2013-08-14 Lys-Pro-Thr KAI Lys-Pro ΩΣ ΕΝΩΣΕΙΣ ΠΟΥ ΑΝΑΣΤΕΛΛΟΥΝ ΤΗ ΦΛΕΓΜΟΝΗ

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20071100596T CY1106563T1 (el) 2001-02-14 2007-05-07 Φλεγμονο-ανασταλτικες ενωσεις

Family Applications After (2)

Application Number Title Priority Date Filing Date
CY20131100431T CY1114024T1 (el) 2001-02-14 2013-05-30 Ενωσεις που αναστελλουν τη φλεγμονη
CY20131100702T CY1114214T1 (el) 2001-02-14 2013-08-14 Lys-Pro-Thr KAI Lys-Pro ΩΣ ΕΝΩΣΕΙΣ ΠΟΥ ΑΝΑΣΤΕΛΛΟΥΝ ΤΗ ΦΛΕΓΜΟΝΗ

Country Status (18)

Country Link
US (4) US8003608B2 (el)
EP (6) EP2198723B1 (el)
JP (1) JP4259870B2 (el)
CN (3) CN101215544B (el)
AT (2) ATE358475T1 (el)
AU (2) AU2002253000B2 (el)
CA (1) CA2437788C (el)
CY (4) CY1106563T1 (el)
DE (3) DE10106852A1 (el)
DK (4) DK1427405T3 (el)
ES (4) ES2361422T3 (el)
HK (4) HK1061980A1 (el)
MX (1) MXPA03007255A (el)
NZ (2) NZ542406A (el)
PL (3) PL221492B1 (el)
PT (4) PT1749524E (el)
SI (4) SI1749524T1 (el)
WO (1) WO2002064131A2 (el)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10106852A1 (de) 2001-02-14 2002-09-05 T Luger Entzündungshemmende Verbindungen
CA2447629A1 (en) * 2001-05-25 2002-12-05 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw The lectin-like domain of thrombomodulin and its therapeutic use
US20090232866A1 (en) 2003-10-07 2009-09-17 Mariann Pavone-Gyongyosi Oligopeptides as coating material for medical products
WO2006009325A1 (ja) * 2004-07-23 2006-01-26 Ono Pharmaceutical Co., Ltd. メタロプロテアーゼ阻害剤
WO2006046746A1 (ja) * 2004-10-26 2006-05-04 Ajinomoto Co., Inc. 内臓痛予防・治療剤
WO2007004613A1 (ja) * 2005-07-01 2007-01-11 Ajinomoto Co., Inc. 炎症性腸疾患治療薬及びＴＮＦ－α産生抑制剤
EP1782819A1 (en) * 2005-11-03 2007-05-09 Cognis IP Management GmbH Oligopeptides and their use
DE102006003854A1 (de) * 2006-01-26 2007-08-02 Universität Duisburg-Essen Regulatorische und cytotoxische CD8+ T-Zellen
AU2008327932B2 (en) * 2007-11-19 2012-05-31 Universitaetsklinikum Muenster Compositions for reducing oxidative stress and uses thereof
US9156881B2 (en) 2011-09-23 2015-10-13 Westfaelische Wilhelms-Universitaet Muenster Tripeptide KDPT for antiapoptotic treatment
CA2864179A1 (en) 2012-03-20 2013-09-26 Lijuan Zhang Short antimicrobial lipopeptides
WO2014183018A2 (en) * 2013-05-10 2014-11-13 Southern Research Institute COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES THROUGH INHIBITING TGF-β ACTIVITY
CN105636975B (zh) 2013-09-23 2019-06-25 奥古斯特沃尔夫博士有限两合公司-医药 抗炎三肽
WO2015067493A1 (en) 2013-11-07 2015-05-14 Dr. August Wolff Gmbh & Co. Kg Arzneimittel Storage stable lyophilized tripeptide formulations
CN107349416A (zh) * 2017-08-01 2017-11-17 中山大学 一种含三肽化合物的抗骨关节炎药物
JP7122018B2 (ja) * 2017-09-15 2022-08-19 カイン サイエンス シーオー．，エルティーディー． 自己免疫疾患および骨疾患の治療剤としてのペプチドの用途
CN111150831B (zh) * 2020-02-27 2023-06-09 广州领晟医疗科技有限公司 多肽KdPT的应用
US11793746B2 (en) * 2020-10-01 2023-10-24 Chanda Zaveri Intense skin hydration systems and methods
CN114432421B (zh) * 2022-01-12 2024-04-12 广州领晟医疗科技有限公司 一种用于治疗急性肺损伤的KdPT多肽及其应用
CN114404562A (zh) * 2022-01-17 2022-04-29 广州领晟医疗科技有限公司 一种用于治疗骨关节炎的KdPT多肽及其应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH676425A5 (el) 1986-08-08 1991-01-31 Univ Texas
US4966848A (en) * 1988-02-08 1990-10-30 The General Hospital Corporation Isolation, purification, characterization, cloning and sequencing of N α-acetyltransferase
EP0335662B1 (en) * 1988-03-28 1995-07-26 Btg International Limited Peptides
ES2012532A6 (es) * 1988-07-15 1990-04-01 Cusi Lab Un procedimiento para la preparacion de una solucion acuosa de b-metil-4-(2' -tienilcarbonil)fenilacetato de lisina para aplicacion topica oftalmica.
DE3844046A1 (de) * 1988-12-28 1990-07-05 Hoerrmann Wilhelm Arzneimittel, die isomere des hydroxylysins oder lysins enthalten
US5223421A (en) * 1989-10-25 1993-06-29 The General Hospital Corporation Identification of methionine Nα-acetyltransferase
ATE142494T1 (de) * 1990-11-30 1996-09-15 Teijin Ltd 2-arylthiazolderivat sowie dieses enthaltendes arzneimittel
CA2153050C (en) * 1993-01-22 1998-12-29 Kelvin Cooper Lysine salt of 6-chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1-carboxamide
GB9413935D0 (en) * 1994-07-11 1994-08-31 Peptech Uk Ltd Use of maramyl peptide compounds
GB9419011D0 (en) * 1994-09-21 1994-11-09 Peptech Uk Ltd Use of muramyl peptide compounds
SE9500270L (sv) * 1995-01-25 1996-09-09 A K J Medi Konsult Ab Läkemedel mot bristtillstånd
CA2212127A1 (en) * 1995-02-03 1996-08-08 Cosmederm Technologies Formulations and methods for reducing skin irritation
FR2733421B1 (fr) 1995-04-28 1997-06-06 Oreal Utilisation de derives de l'hormone stimulatrice des melanocytes de type alpha pour stimuler ou induire la pousse des cheveux et/ou stopper leur chute
US5688489A (en) * 1995-09-15 1997-11-18 Resolution Pharmaceuticals, Inc. Non-receptor mediated imaging agents
US5939394A (en) * 1996-01-18 1999-08-17 Fleming & Company Methods and compositions for the prevention and treatment of immunological disorders, inflammatory diseases and infections
JP3567350B2 (ja) * 1996-03-13 2004-09-22 株式会社ホーネンコーポレーション 抗脱毛症剤
JP3922594B2 (ja) 1996-03-19 2007-05-30 株式会社ノエビア 抗菌性低刺激化粧料
AU3224997A (en) * 1996-05-29 1998-01-05 Prototek, Inc Prodrugs of thalidomide and methods for using same as modulators of t-cell function
US6117896A (en) * 1997-02-10 2000-09-12 Molecumetics Ltd. Methods for regulating transcription factors
EP0934924B1 (en) * 1996-10-11 2008-08-13 Kowa Co. Ltd. Novel diamide compounds and drugs containing the same
AUPO713297A0 (en) * 1997-06-02 1997-06-26 Fujisawa Pharmaceutical Co., Ltd. Oxazole compound
SE9801571D0 (sv) * 1998-05-05 1998-05-05 Wapharm Ab Melanokortin-1-receptorselektiva föreningar
FR2784028B1 (fr) 1998-10-01 2003-02-07 Oreal Utilisation d'un peptide prevenant les reactions d'intolerance de la peau, notamment dans des compositions cosmetiques
JP3962166B2 (ja) * 1998-10-19 2007-08-22 株式会社資生堂 皮膚外用剤
WO2000037071A1 (en) * 1998-12-21 2000-06-29 Aps Kbus 8 Nr. 4788 Topical treatment of skin disease
CA2359636A1 (en) * 1999-01-22 2000-07-27 Andrew W. Taylor Activation of regulatory t cells by alpha-melanocyte stimulating hormone
WO2000054750A1 (fr) * 1999-03-15 2000-09-21 Dmitry Anatolievich Starchenko Procede de correction des perturbations dans la synthese du collagene et substance bioactive de mise en oeuvre de ce procede
CA2415938A1 (en) * 2000-07-14 2002-01-24 Zycos Inc. Alpha-msh related compounds and methods of use
DE10106852A1 (de) 2001-02-14 2002-09-05 T Luger Entzündungshemmende Verbindungen
US7960508B2 (en) 2001-05-11 2011-06-14 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Peptide having cytotoxicity inhibitory activity and method of screening these peptide having cytotoxicity inhibitory activity

Also Published As

Publication number Publication date
ES2361422T3 (es) 2011-06-16
DK2196202T3 (da) 2013-09-08
NZ542406A (en) 2007-04-27
JP4259870B2 (ja) 2009-04-30
US9550807B2 (en) 2017-01-24
PL369526A1 (en) 2005-05-02
CA2437788A1 (en) 2002-08-22
EP2198723B1 (de) 2013-04-10
WO2002064131A2 (de) 2002-08-22
US20170087202A1 (en) 2017-03-30
PL223478B1 (pl) 2016-10-31
SI2198723T1 (sl) 2013-06-28
WO2002064131A3 (de) 2004-04-01
US20040077552A1 (en) 2004-04-22
CN101810847A (zh) 2010-08-25
CY1114024T1 (el) 2016-07-27
EP2260843A2 (de) 2010-12-15
EP1749524B1 (de) 2011-03-23
EP2189156A1 (de) 2010-05-26
CN1541095A (zh) 2004-10-27
CN101215544B (zh) 2011-05-04
AU2002253000B2 (en) 2006-05-25
CA2437788C (en) 2011-04-05
SI1427405T1 (sl) 2007-08-31
CY1106563T1 (el) 2012-01-25
SI2196202T1 (sl) 2013-09-30
DK2198723T3 (da) 2013-06-17
HK1061980A1 (en) 2004-12-10
CN101810847B (zh) 2013-02-13
JP2004533995A (ja) 2004-11-11
PT1749524E (pt) 2011-05-25
EP1749524A2 (de) 2007-02-07
US10046020B2 (en) 2018-08-14
PT2196202E (pt) 2013-09-24
PL223229B1 (pl) 2016-10-31
PT1427405E (pt) 2007-05-31
US8003608B2 (en) 2011-08-23
SI1749524T1 (sl) 2011-08-31
ATE502632T1 (de) 2011-04-15
PL391884A1 (pl) 2010-09-13
ES2281511T3 (es) 2007-10-01
NZ528191A (en) 2005-11-25
ES2411935T3 (es) 2013-07-09
AU2006203622A1 (en) 2006-09-07
EP1427405B1 (de) 2007-04-04
EP2196202A1 (de) 2010-06-16
EP1749524A3 (de) 2007-11-28
CN101215544A (zh) 2008-07-09
PT2198723E (pt) 2013-06-12
DE10106852A1 (de) 2002-09-05
CY1114214T1 (el) 2016-08-31
HK1140915A1 (en) 2010-10-29
DE50209873D1 (de) 2007-05-16
HK1140960A1 (en) 2010-10-29
PL221492B1 (pl) 2016-04-29
DK1749524T3 (da) 2011-06-06
EP2198723A1 (de) 2010-06-23
CN1269477C (zh) 2006-08-16
DK1427405T3 (da) 2007-07-02
EP1427405A2 (de) 2004-06-16
EP2196202B1 (de) 2013-07-17
DE50214981D1 (de) 2011-05-05
EP2260843A3 (de) 2011-08-03
MXPA03007255A (es) 2005-02-14
US20150087578A1 (en) 2015-03-26
ES2427970T3 (es) 2013-11-05
US20120045462A1 (en) 2012-02-23
PL391988A1 (pl) 2010-09-13
ATE358475T1 (de) 2007-04-15
AU2006203622B2 (en) 2007-08-09
HK1095538A1 (en) 2007-05-11
US8846617B2 (en) 2014-09-30

Similar Documents

Publication Publication Date Title
CY1111450T1 (el) Ενωσεις που αναστελλουν τη φλεγμονη
NL300877I2 (nl) obeticholzuur
EA200601686A1 (ru) Замещенные производные морфолина и тиоморфолина
DK1519724T3 (da) Fredericamycin-derivater som lægemidler til behandling af tumorer
MX2007005694A (es) Nuevos derivados de betulina, preparacion y uso de los mismos.
CY1109497T1 (el) Παραγωγα θειοφενιου ως αντιβιοτικοι παραγοντες για λοιμωξη/μολυνση φλαβοϊου (flavivirus)
DE69830504D1 (de) Antithrombotische mitteln
CY1108707T1 (el) Αναλογα νοσισεπτινης
HRP20080382A2 (en) LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR Xa INHIBITORS
CY1111481T1 (el) Υποκατεστημενα αρυλοκυκλοπροπυλακεταμιδια ως ενεργοποιητες γλυκοκινασης
CY1106801T1 (el) Νεες ετεροκυκλικες ενωσεις, η παρασκευη τους και η χρηση τους ως φαρμακα, ιδιαιτερα ως αντιβακτηριακα
BR0109703A (pt) Derivados de piperazina
CY1108729T1 (el) 3,11b-cis-διυδpotetpabenazinh για την θεραπευτικη αντιμετωπιση μιας πολλαπλασιαστικης νοσου ή φλεγμονωδους παθησης
EA200800302A1 (ru) Применение производных и аналогов тиазола при лечении рака
SE0101932D0 (sv) Pharmaceutical combinations
CY1108632T1 (el) Παραγωγα της 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline για θεραπεια της στειροτητας
MXPA04006041A (es) Antivirales de piridoquinoxalina.
DE60104697D1 (de) Sulfonamid-derivate
MXPA05006889A (es) Compuestos aromaticos como agentes anti-inflamatorios, inmunomoduladores y anti-proliferativos.
MXPA05009282A (es) Derivados de anilina sustituidos.
ATE424200T1 (de) Solubilisierte topoisomerase-gift-mittel
ATE308540T1 (de) Antithrombosemittel
EA200501900A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей
EA200600898A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей
EA200501925A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей